KTI A2.0MAb
Latest Information Update: 06 Aug 2021
At a glance
- Originator Keros Therapeutics
- Class Antianaemics; Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anaemia
Most Recent Events
- 09 Jun 2021 Pharmacodynamics and pharmacokinetics data from preclinical studies in Iron deficiency anaemia and anaemia presented at 26th Congress of the European Haematology Association (EHA-2021)
- 05 Dec 2020 Preclinical trials in Anaemia in USA (unspecified route)
- 05 Dec 2020 Pharmacodynamics data from a preclinical study in Anaemia at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)